Biofrontera Inc. (BFRIW) stock
BFRIWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BFRI
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 10/30
$0.00+0.00 (0.00%)
Close on Oct 30, 2026Market cap $12.96MP/E –Yield –
Biofrontera r&d expenses
Research and development expenses are spending on new products and technology.
Biofrontera's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.99M, down 15.3% year over year. For fiscal 2025 it was $3.72M, up 78.0% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.72M | +78.0% |
| FY2024 | Dec 31, 2024 | $2.09M | +2613.0% |
| FY2023 | Dec 31, 2023 | $77.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $448.00K | -48.5% |
| Q1 FY2026 | Mar 31, 2026 | $900.00K | -25.4% |
| Q4 FY2025 | Dec 31, 2025 | $787.00K | +0.5% |
| Q3 FY2025 | Sep 30, 2025 | $854.00K | +27.7% |
| Q2 FY2025 | Jun 30, 2025 | $870.00K | +40.1% |
| Q1 FY2025 | Mar 31, 2025 | $1.21M | +7000.0% |
| Q4 FY2024 | Dec 31, 2024 | $783.00K | +2272.7% |
| Q3 FY2024 | Sep 30, 2024 | $669.00K | +1927.3% |
| Q2 FY2024 | Jun 30, 2024 | $621.00K | +5545.5% |
| Q1 FY2024 | Mar 31, 2024 | $17.00K | – |
| Q4 FY2023 | Dec 31, 2023 | $33.00K | – |
| Q3 FY2023 | Sep 30, 2023 | $33.00K | – |
| Q2 FY2023 | Jun 30, 2023 | $11.00K | – |